Compare OKTA & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OKTA | ZBH |
|---|---|---|
| Founded | 2009 | 1927 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Industrial Specialties |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.2B | 19.9B |
| IPO Year | 2017 | N/A |
| Metric | OKTA | ZBH |
|---|---|---|
| Price | $85.82 | $94.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 39 | 19 |
| Target Price | ★ $116.22 | $108.56 |
| AVG Volume (30 Days) | ★ 2.9M | 2.1M |
| Earning Date | 12-02-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 1.02% |
| EPS Growth | ★ N/A | N/A |
| EPS | 1.08 | ★ 4.03 |
| Revenue | $2,840,000,000.00 | ★ $8,010,900,000.00 |
| Revenue This Year | $12.76 | $8.20 |
| Revenue Next Year | $9.34 | $5.92 |
| P/E Ratio | $79.89 | ★ $23.38 |
| Revenue Growth | ★ 12.12 | 5.47 |
| 52 Week Low | $75.05 | $85.33 |
| 52 Week High | $127.57 | $114.44 |
| Indicator | OKTA | ZBH |
|---|---|---|
| Relative Strength Index (RSI) | 55.88 | 49.85 |
| Support Level | $75.05 | $92.14 |
| Resistance Level | $88.02 | $98.34 |
| Average True Range (ATR) | 2.97 | 1.99 |
| MACD | 0.91 | 0.49 |
| Stochastic Oscillator | 83.04 | 58.27 |
Okta is a cloud-native security company that focuses on identity and access management. The San Francisco-based firm went public in 2017 and focuses on two key client stakeholder groups: workforces and customers. Okta's workforce offerings enable a company's employees to securely access its cloud-based and on-premises resources. The firm's customer offerings allow its clients' customers to securely access the client's applications.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.